Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable neutralizing antibody titers (NAbT) against SARS-CoV-2 variants of concern (VOCs) vs wildtype (WT). Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT vs solid cancers against both WT and VOCs. In comparison with individuals without cancer, patients with haematological, but not solid, malignancies had reduced NAb responses. Seroconversion showed poor concordance with NAbT against VOCs. Prior SARS-CoV-2 infection boosted NAb response including against VOCs, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T-cell responses were detected in 80% of patients, and were comparable between vaccines or cancer types. Our results have implications for the management of cancer patients during the ongoing COVID-19 pandemic.
CAPTURE（NCT03226886）是一项关于癌症患者 COVID-19 免疫的前瞻性队列研究。在这里，我们评估了在间隔 12 周接受两剂 BNT162b2 或 AZD1222 疫苗接种的 585 例患者。在实体瘤和血液恶性肿瘤患者中，两剂后血清转化率分别为 85%和 59%。与野生型（WT）相比，针对 SARS-CoV-2 关注变异株（VOCs）的可检测中和抗体滴度（NAbT）的患者比例较低。血液恶性肿瘤患者的 NAbT 更难以检测到，并且与 WT 和 VOCs 相比，其 NAbT 的中位数均低于实体瘤。与无癌症的个体相比，血液恶性肿瘤患者的 NAb 反应降低，但实体瘤患者的 NAb 反应没有降低。血清转化率与针对 VOCs 的 NAbT 一致性较差。先前的 SARS-CoV-2 感染增强了 NAb 反应，包括针对 VOCs 的反应，而抗 CD20 治疗与无法检测到的 NAbT 相关。在 80%的患者中检测到疫苗诱导的 T 细胞反应，并且在疫苗或癌症类型之间具有可比性。我们的研究结果对当前 COVID-19 大流行期间癌症患者的管理具有重要意义。
